Pharma News: Alnylam, Lilly, Merck, Pfizer, Novo Nordisk Updates

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we have a deep probe into Moderna’s travails from STAT’s tireless Jason Mast. Also, a pharma bidding war, thoughts on psychedelic regulation, and the Trump administartion is trying to fast-track cheaper biosimilars.

The need-to-know this morning

Moderna’s mRNA empire stumbles amid politics, retrenchment

Once seemingly on top of the world, Moderna now faces a brutal reset.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans